,ug/ml; DAQ 2A, 1.39 ,ug/ml; amphotericin B, 1.03 ,ug/ml; and flucytosine, 0.72 ,tg/ml. An additional seven DAQ compounds were tested but showed less or no activity against 17 Candida isolates. Forty-eight-hour viability studies with DAQ 2A alone or in combination with amphotericin B, flucytosine, or sulfamethoxazole were carried out with one isolate of intermediate susceptibility to each of these agents except sulfamethoxazole. For this isolate the combination of DAQ 2A and sulfamethoxazole was synergistic, and the combination of DAQ 2A and AMB was either synergistic or additive, whereas the combination of DAQ 2A and flucytosine was antagonistic. Although regrowth of cultures exposed to DAQ 2A was noted over a 48-h period, neither degradation of the drug nor development of resistance to the drug could be detected. Swiss white mice receiving DAQ 1A at a dose of 6 mg/kg for 5 days showed no obvious signs of toxicity, including weight loss.
Currently there are two agents available for the treatment of systemic Candida infections, amphotericin B (AMB) and flucytosine (FC) (5-7, 12). Because of limitations associated with each agent, efforts continue to develop additional drugs with activity against these species. Members of the 2,4-diaminoquinazoline (DAQ) class of compounds, which are antifolates, were shown by Hynes et al. (17) Media. Synthetic amino acid medium-fungal (SAAMF) was utilized and was kindly supplied by John R. Dixon (Grand Island Biological Co., Product Development Office, Lawrence, Mass.). This completely defined medium has been shown to have a number of advantages for the in vitro testing of antifungal compounds (14, 16) .
Drugs. H. E. Album of Wyeth Laboratories, Philadelphia, Pa., provided five of the DAQ drugs tested (Fig. 1 , compounds 1A to 5A), and the other four DAQ drugs (Fig. 1, In these viability experiments the initial concentration of Candida organisms ranged between 104 and 105 colony-forming units per nl. Each of the drugs was employed at a concentration equal to its MIC, except for SMX which was inactive against the Candida isolate used at 50 ug/ml and was utilized at this concentration. DAQ 2A was also used at a 10-fold-higher concentration in experiments for studying its effect when combined with SMX. In these experiments the concentration of Me2SO was also maintained at less than 1%, and the flasks were incubated in a shaking water bath at 37°C for 48 h, with a sample of 0.5 ml taken at 0, 3, 6, 9, 12, 24, 30 and 48 h. Serial dilutions were plated out of each sample to determine the number of viable organisms. Fungal growth without any drug was run 11 times in the course of these experiments, and a control curve was constructed from all of these so that these curves are identical for Fig.  2, 3 , and 4. The effect of DAQ 2A at 0.75 ,ug/ml was repeated eight times, and a single curve was constructed from these data and is depicted in Fig. 3 and 4. All the other agents and combinations were run four times, except DAQ 2A at 7.5 ,Lg/ml, SMX, and the combination (Fig. 2) , which were run three times each.
Drug stability and resistance development. The stability of DAQ 2A (at 7.5 ug/ml) was studied by taking samples from times 0 and 48 h from two flasks treated exactly like those in the viability study except that only one was inoculated with Candida. The fungistatic activity of the supernatants, obtained by centrifugation, was then determined with the microtiter system. Also, an attempt was made to detect resistance development by repeating the MIC determination of the isolate used in the viability studies after 48 h of exposure to DAQ 2A at a concentration of 0.75 ,ug/ml. Toxicity experiment. ICR Swiss female white mice weighing between 22 and 25 g were treated with 6 mg of DAQ 1A per kg per day administered intraperitoneally for 5 days. Six animals were given the drug and six animals were given Me2SO, and their weights were determined daily. Fig. 2, 3 , and 4. Figure 2 shows the effect of DAQ 2A, SMX, and the combination of both agents on the growth of Candida. The combination resulted in more pronounced killing of the organism, and regrowth occurred later and to a lesser degree, indicating that an inactive concentration of SMX was sufficient to markedly augment the action of DAQ 2A. The regrowth of the organism after 24 h of exposure to DAQ 2A was marked, so that by 48 h the original concentration of organisms was slightly exceeded. Figure 3 demonstrates the effect of DAQ 2A, AMB, and the combination of both agents on Candida growth. AMB resulted in more than a 10-fold reduction in numbers of Candida organisms when compared with the control at 12 h, although by 48 h considerable regrowth had occurred. The most striking effect of the combination of DAQ 2A and AMB was to delay regrowth of the organisms after 12 h.
RESULTS
The effects of DAQ 2A, FC and the combination of both agents on Candida growth are shown in Fig. 4 . FC retards growth of the yeast, but when combined with DAQ 2A the growth curve is similar to the control curve. DAQ 2A alone results in slower growth initially, but by 30 h the concentration of organisms is equal to that of the control. It should be noted that these viability studies employed an inoculum 10 times greater than that used to determine MICs. This may explain why some of these drugs, despite being used at a concentration equal to the MIC of the Candida isolate, only minimally inhibited its growth.
Resistance development to DAQ 2A was not detected because the MIC of the isolate (0.75 ,ug/ml) used in the viability studies was not significantly different from that obtained after 48 h of exposure to the drug (1.5 ,a.g/ml or one twofold dilution). In addition, 0-and 48-h samples of SAAMF, containing an initial DAQ 2A concentration of 7.5 t&g/ml in the presence and absence of organisms, were both effective at a 1: 8 dilution in inhibiting the organism used in the viability studies.
Finally, mice given 6 mg of DAQ 1A per kg per day for 5 days showed no weight loss or other signs of toxicity. DISCUSSION The data in Table 1 show that two new DAQ compounds, DAQ 1A and DAQ 2A, were as effective as AMB and FC in inhibiting the growth of 40 Candida isolates. However, AMB acted fungicidally, whereas the DAQ drugs were more similar to FC in that only occasional isolates were killed by lower drug concentrations. However, from the viability experiments it was evident that if the concentration of drug was increased 10-fold against the same isolate, killing of the organism occurred (compare Fig. 2 and 3) .
The which is demonstrated by the slower regrowth of the organism but not by greater killing, is of considerable interest. To explain this enhanced activity one can propose that AMB acts on the fungal cell membrane to increase its permeability to other drugs (19) . This interpretation may be the explanation for the enhancement, by AMB, of the activity of FC (20) , clotrimazole (4) and antimicrobials such as rifampin (3) and some tetracyclines (1, 18) The regrowth of Candida when exposed to 7.5 jig of DAQ 2A per ml is puzzling because no breakdown of the drug could be detected during the 48-h incubation period, nor did the isolate develop resistance to the drug during this time. We have no explanation for this phenomenon. The regrowth observed after 12 h of exposure to AMB is probably related to the breakdown of this material in SAAMF (15) .
The in vivo activity of some DAQ compounds and the lack of obvious toxicity in the mouse of one of the most active of these compounds encourage further work on the use of these drugs as antifungal agents in animal models. Furthermore, if activity can be shown in an animal model, potentiation of activity should be sought by utilizing combinations of DAQ compounds with sulfonamides or AMB.
